Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics Inc. (CDTX)
:CDTX
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.68Last Year’s EPS
-19.99Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 33.16%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Neutral
The earnings call emphasizes significant progress in the development of CD388, demonstrating promising results in early trials and advancing to a phase 2b study. There is optimism around the potential phase 3 study and the commercial opportunity, highlighted by the planned R&D day. However, the company's current non-revenue generating status and challenges with the NAVIGATE study's design and dose-dependent efficacy present notable concerns.Company Guidance
During the earnings call for the first quarter of 2025, Cidara Therapeutics, Inc. focused on the progress of their lead asset, CD388, a novel drug designed to prevent influenza. The company highlighted the completion of dosing for the phase 2b NAVIGATE study, which involved 5,041 subjects randomized into three dose groups (150 mg, 300 mg, or 450 mg) and one placebo group. Top-line data from this study, which was not initially powered for statistical significance, are expected by June 2025. Due to the severity of the February 2025 flu season, Cidara is in discussions with the FDA to potentially amend the study's statistical analysis to evaluate the statistical significance of CD388's efficacy. CD388 has shown promise in preclinical and early-phase clinical trials, demonstrating substantial protective efficacy and a well-tolerated safety profile, with potential broad applications beyond the initial target populations. The company plans to initiate a phase 3 study in the Southern Hemisphere in February 2026, focusing on high-risk and immune-compromised populations.Introduction of CD388
CD388 aims to revolutionize the prevention of influenza by offering universal activity against all flu strains, not dependent on the host immune system, and combines a novel multivalent presentation of zanamivir with a human antibody fragment to prolong half-life.
Successful Phase 1 and Phase 2a Trials
Phase 1 single ascending dose study showed CD388 to be well tolerated with an extended half-life. Phase 2a human challenge study showed substantial protective efficacy, supporting its advancement to a phase 2b study.
Progress of NAVIGATE Phase 2b Study
NAVIGATE study completed dosing of 5,041 subjects by December, with top-line data expected by June. The study aims to determine dose selection for phase three.
Potential Phase 3 Study
Based on phase 2b results and FDA discussions, a phase 3 study is planned for February in high-risk comorbid and immune-compromised patients, addressing unmet needs.
R&D Day Announcement
An R&D day is planned for May 22 to provide updates on the NAVIGATE trial, regulatory discussions, and phase 3 plans, emphasizing the potential commercial opportunity for CD388.
---
CDTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CDTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $19.15 | $18.63 | -2.72% |
Mar 06, 2025 | $23.61 | $23.66 | +0.21% |
Nov 07, 2024 | $13.11 | $13.50 | +2.97% |
Aug 13, 2024 | $12.15 | $12.86 | +5.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cidara Therapeutics Inc. (CDTX) report earnings?
Cidara Therapeutics Inc. (CDTX) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Cidara Therapeutics Inc. (CDTX) earnings time?
Cidara Therapeutics Inc. (CDTX) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDTX EPS forecast?
CDTX EPS forecast for the fiscal quarter 2025 (Q2) is -1.68.
---